Tigem
Alberto Auricchio serves as the Scientific Director and Principal Investigator at Tigem since September 2002 and has been the Coordinator of the Molecular Therapy programme. Within the academic sector, Alberto Auricchio holds multiple roles at the University of Naples Federico II, including Faculty Lecturer in Medical Genetics and Full Professor of Medical Genetics in the Department of Advanced Biomedical Sciences. Additionally, Alberto Auricchio is the Vice President of the European Society of Gene and Cell Therapy and has contributed to various positions, including Founder and Chief Scientific Officer at AAVantgarde Bio, and Founder and Consultant at InnovaVector. The educational background includes extensive training at the University of Pennsylvania, culminating in several postdoctoral degrees, and prior medical training at Università degli Studi di Napoli Federico II and Università degli Studi di Milano.
This person is not in any teams
This person is not in any offices
Tigem
The Telethon Institute of Genetics and Medicine (TIGEM) is a multidisciplinary research Institute devoted to studying the mechanisms underlying rare genetic diseases and to developing innovative therapies. With the support of Fondazione Telethon, the European Community and many other funding agencies, TIGEM's research groups are engaged in numerous clinical trials and collaborative projects. In addition, TIGEM's alliances with various universities offer the Institute additional resources and provide opportunities for excellent students. TIGEM is a Telethon Foundation research centre in Pozzuoli, Italy. TIGEM comprises several research groups and over 200 staff members, all dedicated to understanding the molecular mechanisms behind rare genetic diseases and developing novel treatments. These diseases, often overlooked by pharmaceutical industries, are most common in children and adolescents. TIGEM’s research falls into three main themes: Cell Biology and Disease Mechanisms, Genomic Medicine, and Molecular Therapy. Our research is supported by a number of in-house highly specialised facilities, as well as significant international support in the form of funding and collaborative opportunities.